Tenaya Shares Rise on Positive Data From ARVC Study

Dow Jones

05/15

By Nicholas G. Miller

Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy.

The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months.

The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions.

Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to "decrease the risk for more serious, life-threatening arrhythmias."

The therapy was also well-tolerated at both dose levels in the study, the company said

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

May 15, 2026 07:14 ET (11:14 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2635862200"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635862200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635862200?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635862200","market":"sg","top_or_hot":-1,"title":"Tenaya Shares Rise on Positive Data From ARVC Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n</p>\n<p>\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n</p>\n<p>\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n</p>\n<p>\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n</p>\n<p>\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Shares Rise on Positive Data From ARVC Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Shares Rise on Positive Data From ARVC Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 19:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n</p>\n<p>\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n</p>\n<p>\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n</p>\n<p>\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n</p>\n<p>\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635862200","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635862200","pubTimestamp":1778843640,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy.The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months.The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions.Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\". The therapy was also well-tolerated at both dose levels in the study, the company said","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","TNYA":"Tenaya Therapeutics Inc"},"translate_title":"ARVC研究的积极数据使Tenaya股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n\n\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n\n\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n\n\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n\n\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 07:14 ET (11:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}